Rna-targeting small molecule NPC86 for multiple sclerosis therapy

Overview

NPC86 is a small molecule therapeutic designed to stabilize long non-coding RNA GAS5, a regulatory RNA implicated in neuroinflammation and tau phosphorylation. Aberrant GAS5 expression has been linked to multiple sclerosis (MS) and progressive MS, where it contributes to CNS inflammation and neuronal damage. By restoring GAS5 to normal physiological levels, NPC86 aims to decrease neuroinflammation through the toll-like receptor pathway and reduce abnormal tau phosphorylation, two central mechanisms in MS pathogenesis. The compound has demonstrated in vivo efficacy when delivered intranasally, offering a non-invasive route of administration that does not require a carrier. This approach represents a novel RNA-targeting strategy for slowing or preventing the progression of neurodegenerative diseases such as MS.

Technical specifications

• Target: Long non-coding RNA GAS5, stabilized by NPC86 to restore physiological expression levels
• Mechanism: Modulates two key pathways in MS pathogenesis—neuroinflammation via the toll-like receptor pathway and tau expression and phosphorylation in the brain
• Delivery: Intranasal administration, non-invasive and carrier-free
• Validation methods: qPCR for RNA expression, western blot for protein analysis, immunohistochemistry (H&E staining), Ki67 and doublecortin staining in the subgranular zone of the dentate gyrus, and stereological quantification using Stereo Investigator software
• Dosing range tested: Optimized at 100 ng/kg in aged mouse models; higher doses proposed for EAE evaluation
• Outcome measures for future studies: Rotarod and Y-maze for cognitive and motor function; Iba1 immunohistochemistry for microglia; phospho-tau and total tau analysis; LFB staining for myelin loss; H&E for inflammatory cell infiltration; RNAseq followed by qPCR and western blot validation
• Statistical rigor: One-way ANOVA with significance thresholds of p<0.001, p<0.01, and p<0.05

Technology readiness level

NPC86 has been validated in vivo in young (4 months) and aged (20 months) C57BL/6J mice, demonstrating safety, efficacy, target engagement, and dose-dependent responses. Published findings confirm decreased neuroinflammation and tau phosphorylation in the brain following treatment. The compound is ready for evaluation in the experimental autoimmune encephalomyelitis (EAE) mouse model, the standard preclinical MS model. Proposed next phases include determining the optimal dose for motor outcomes and assessing whether NPC86 can both prevent the onset of MS-like pathology and reverse established disease. Future validation will expand into EAE cohorts with comprehensive cognitive, motor, histological, and biochemical endpoints to advance toward translational development.